Learn about CBG with Gooey Rabinski's White Paper

This article is brought to you by the new Higher Learning LV Core Cannabis course. Learn the 25 most important cannabinoids and eight most common terpenes for an affordable enrollment fee of only $240.

Learn about CBG with Gooey Rabinski's White Paper. In 2019, I wrote a white paper about the hemp-derived cannabinoid cannabigerol (CBG) for a client in Oregon. The client company has since been sold and the white paper abandoned from the brand's website.

This 50-page and richly illustrated white paper details a number of elements of CBG and the overall issue of humans consuming hemp and cannabis. It includes more than 130 citations to peer-reviewed research studies. This science-based white paper is an excellent primer for cannabis and hemp industry professionals wishing to better understand the delicate biochemistry of hemp and pivotal phytomolecules such as CBG.

Below is an excerpt from my CBG white paper:

"Cannabigerol, or CBG, is one of a family of more than 100 molecules called cannabinoids that are produced by cannabis. CBG is unique among its peers due to the pivotal role that it plays in the synthesis of other cannabinoids and the overall chemical composition of the plant. This fact would be trivial if not for the considerable potential of this family of molecules for humans (and all mammals) that has been revealed by thousands of peer-reviewed research studies (citations appear throughout this white paper)."

Here's another sample from this pivotal and unique white paper:

Acidic precursors, indicated by an "A" following the cannabinoid name (and sometimes denoted as CBD-A or CBDa), are best considered the "larval stage" of a cannabinoid. Each analog of an acidic precursor delivers its own distinct set of medicinal qualities. Thus, a consumer might gain greater value from consuming both CBGA and CBG (depending on dosing and their specific condition) than either of these cannabinoids individually.

 "In clinical practice, we often see cannabis products that contain large amounts of CBGA providing impressive value for patients who struggle with bowel diseases, such as irritable bowel syndrome, Crohn's disease, ulcerative colitis, and recurrent nausea," said Dr. Ben Caplan, a Boston-based family physician and founder of the CED Foundation, in an exclusive interview for this white paper.

If you enjoyed and learned from this ad-free and no-cost article, share it with your colleagues and friends.

— Gooey Rabinski

Are you a cannabis industry professional? Check out Higher Learning LV's Deep Dive Subscription that features dozens of long-form articles based on the latest peer-reviewed scientific research. Priced to accommodate personal and enterprise training budgets.